These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 24606432)
41. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study. Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G; Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414 [TBL] [Abstract][Full Text] [Related]
42. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients. Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112 [TBL] [Abstract][Full Text] [Related]
43. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy. Nishio S; Katsumata N; Matsumoto K; Tanabe H; Yonemori K; Kouno T; Shimizu C; Ando M; Kamura T; Kasamatsu T; Fujiwara Y J Cancer Res Clin Oncol; 2009 Apr; 135(4):551-7. PubMed ID: 18830625 [TBL] [Abstract][Full Text] [Related]
44. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. Naumann RW; Coleman RL; Burger RA; Sausville EA; Kutarska E; Ghamande SA; Gabrail NY; Depasquale SE; Nowara E; Gilbert L; Gersh RH; Teneriello MG; Harb WA; Konstantinopoulos PA; Penson RT; Symanowski JT; Lovejoy CD; Leamon CP; Morgenstern DE; Messmann RA J Clin Oncol; 2013 Dec; 31(35):4400-6. PubMed ID: 24127448 [TBL] [Abstract][Full Text] [Related]
45. Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: time to think differently? Friedlander ML; Stockler MR; Butow P; King MT; McAlpine J; Tinker A; Ledermann JA J Clin Oncol; 2013 Jun; 31(18):2362. PubMed ID: 23669225 [No Abstract] [Full Text] [Related]
46. The Safety of Pegylated Liposomal Doxorubicin Plus Irinotecan in Recurrent Ovarian Cancer Patients: A Phase I Trial. Miyahara D; Ueda T; Katsuda T; Maehara M; Fukagawa S; Miyata K; Nam SO; Kondo H; Miyamoto S Anticancer Res; 2015 Aug; 35(8):4521-5. PubMed ID: 26168496 [TBL] [Abstract][Full Text] [Related]
47. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557 [TBL] [Abstract][Full Text] [Related]
48. Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer. Mayer C; Brucker J; Schuetz F; Domschke C; Bechstein S; Heil J; Golatta M; Wallwiener M; Sohn C; Schneeweiss A; Rom J Arch Gynecol Obstet; 2016 Jul; 294(1):123-9. PubMed ID: 26498757 [TBL] [Abstract][Full Text] [Related]
49. Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers. Kudoh K; Takano M; Kouta H; Kikuchi R; Kita T; Miyamoto M; Watanabe A; Kato M; Goto T; Kikuchi Y Gynecol Oncol; 2011 Aug; 122(2):233-7. PubMed ID: 21601912 [TBL] [Abstract][Full Text] [Related]
50. Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity. Steppan I; Reimer D; Sevelda U; Ulmer H; Marth C; Zeimet AG Chemotherapy; 2009; 55(6):391-8. PubMed ID: 19955744 [TBL] [Abstract][Full Text] [Related]
51. Suppressive effect upon carboplatin hypersensitivity reaction via pegylated liposomal doxorubicin combination therapy. Shimada K; Nagao S; Suzuki K; Shibutani T; Yamamoto K; Jimi T; Yano H; Kitai M; Shiozaki T; Yamaguchi S Int J Clin Oncol; 2020 Sep; 25(9):1718-1725. PubMed ID: 32447473 [TBL] [Abstract][Full Text] [Related]
53. Epithelial ovarian cancer: role of pegylated liposomal Doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treatment. Tanguay JS; Ansari J; Buckley L; Fernando I Int J Gynecol Cancer; 2009 Apr; 19(3):361-6. PubMed ID: 19407560 [TBL] [Abstract][Full Text] [Related]
54. Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients. Tangjitgamol S; See HT; Manusirivithaya S; Levenback CF; Gershenson DM; Kavanagh JJ Int J Gynecol Cancer; 2004; 14(5):804-14. PubMed ID: 15361188 [TBL] [Abstract][Full Text] [Related]
55. Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum. Silver DF; Piver MS Am J Clin Oncol; 1999 Oct; 22(5):450-2. PubMed ID: 10521056 [TBL] [Abstract][Full Text] [Related]
56. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330 [TBL] [Abstract][Full Text] [Related]
57. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. Teneriello MG; Tseng PC; Crozier M; Encarnacion C; Hancock K; Messing MJ; Boehm KA; Williams A; Asmar L J Clin Oncol; 2009 Mar; 27(9):1426-31. PubMed ID: 19224848 [TBL] [Abstract][Full Text] [Related]
58. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study. Power P; Stuart G; Oza A; Provencher D; Bentley JR; Miller WH; Pouliot JF Gynecol Oncol; 2009 Sep; 114(3):410-4. PubMed ID: 19520420 [TBL] [Abstract][Full Text] [Related]
59. Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study. Friedlander ML; Stockler M; O'Connell R; Voysey M; Oza A; Gillies K; Donovan H; Martyn J; Sjoquist K; Butow P; King MT; Int J Gynecol Cancer; 2014 Jun; 24(5):857-64. PubMed ID: 24844219 [TBL] [Abstract][Full Text] [Related]
60. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer. Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]